天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> Expert opinion on investigational drugs >>article
Expert opinion on investigational drugs

Expert opinion on investigational drugs

IF: 4.9
Download PDF

Retatrutide showing promise in obesity (and type 2 diabetes).

Published:1 July 2023 DOI: 10.1080/13543784.2023.2283020 PMID: 37947489
Sheila A Doggrell

Abstract

Introduction: Obesity is a major risk factor for cardiovascular disease, diabetes, osteoarthritis, and some cancers. Retatrutide stimulates Glucagon-like peptide 1 (GLP-1), Glucose-dependent insulinotropic polypeptide (GIP) receptors, and glucagon receptors, and is being developed for the treatment of obesity and type 2 diabetes.

Areas covered: A phase 2 clinical trial of retatrutide (LY3437943) in the treatment of obesity. The primary end point was percentage change in weight from baseline to 24?weeks, which ranged from -7.2% to -~18% as the dose of retatrutide increased from 1?mg to 12?mg. The most frequent adverse events were gastrointestinal (nausea, diarrhea, vomiting).

Expert opinion: The results for retatrutide in phase 2 for obesity (and diabetes) are mostly encouraging. Consistent with being a GLP-1 receptor agonist, heart rate was increased by up to 6.7 beats/min by retatrutide, which may be detrimental and offset some of the benefits of weight loss. Presumably, retatrutide is being developed as a challenger to the recently developed weight loss medicines; semaglutide and/or tirzepatide. Thus, comparator studies are needed between retatrutide and these drugs, but none are ongoing and, in my opinion, this lack is a major omission in the development of retatrutide.

Substances (3)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Semaglutide 910463-68-2 C187H291N45O59 509 suppliers Inquiry
Tirzepatide 2023788-19-2 294 suppliers Inquiry
Retatrutide 2381089-83-2 166 suppliers Inquiry

Similar articles

IF:13

Linagliptin: in type 2 diabetes mellitus.

Drugs Lesley J Scott,etc Published: 26 March 2011
IF:13

Dapagliflozin: A Review in Type 2 Diabetes.

Drugs Sohita Dhillon,etc Published: 1 July 2019
IF:2.5

Efficacy of voglibose in type 2 diabetes.

Expert Opinion on Pharmacotherapy Kohei Kaku,etc Published: 1 June 2014